- Home
- CAPR vs BYRN Comparison
CAPR vs BYRN Comparison
Compare CAPR & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- BYRN
- Stock Information
- Founded
- CAPR 2005
- BYRN 2005
- Country
- CAPR United States
- BYRN United States
- Employees
- CAPR N/A
- BYRN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- BYRN Industrial Machinery/Components
- Sector
- CAPR Health Care
- BYRN Miscellaneous
- Exchange
- CAPR Nasdaq
- BYRN Nasdaq
- Market Cap
- CAPR 525.3M
- BYRN 626.0M
- IPO Year
- CAPR N/A
- BYRN N/A
- Fundamental
- Price
- CAPR $9.48
- BYRN $16.71
- Analyst Decision
- CAPR Strong Buy
- BYRN Strong Buy
- Analyst Count
- CAPR 7
- BYRN 3
- Target Price
- CAPR $39.29
- BYRN $22.08
- AVG Volume (30 Days)
- CAPR 1.5M
- BYRN 655.8K
- Earning Date
- CAPR 03-19-2025
- BYRN 04-10-2025
- Dividend Yield
- CAPR N/A
- BYRN N/A
- EPS Growth
- CAPR N/A
- BYRN N/A
- EPS
- CAPR N/A
- BYRN 0.55
- Revenue
- CAPR $22,270,465.00
- BYRN $85,756,000.00
- Revenue This Year
- CAPR $34.33
- BYRN $30.15
- Revenue Next Year
- CAPR $246.72
- BYRN $22.53
- P/E Ratio
- CAPR N/A
- BYRN $30.17
- Revenue Growth
- CAPR N/A
- BYRN 101.10
- 52 Week Low
- CAPR $3.52
- BYRN $7.79
- 52 Week High
- CAPR $23.40
- BYRN $34.78
- Technical
- Relative Strength Index (RSI)
- CAPR 33.11
- BYRN 30.05
- Support Level
- CAPR $12.64
- BYRN $17.82
- Resistance Level
- CAPR $13.81
- BYRN $18.36
- Average True Range (ATR)
- CAPR 1.18
- BYRN 1.16
- MACD
- CAPR -0.32
- BYRN 0.03
- Stochastic Oscillator
- CAPR 9.83
- BYRN 10.13
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.